173 related articles for article (PubMed ID: 27659012)
41. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer.
Liu CL; Chen SF; Wu MZ; Jao SW; Lin YS; Yang CY; Lee TY; Wen LW; Lan GL; Nieh S
Oncotarget; 2016 Mar; 7(12):14279-90. PubMed ID: 26872057
[TBL] [Abstract][Full Text] [Related]
42. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
[TBL] [Abstract][Full Text] [Related]
43. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
Namkaew J; Zhang J; Yamakawa N; Hamada Y; Tsugawa K; Oyadomari M; Miyake M; Katagiri T; Oyadomari S
Cancer Lett; 2024 Feb; 582():216509. PubMed ID: 38036042
[TBL] [Abstract][Full Text] [Related]
44. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
45. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
46. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines.
Cetintas VB; Kucukaslan AS; Kosova B; Tetik A; Selvi N; Cok G; Gunduz C; Eroglu Z
Cell Biol Int; 2012 Mar; 36(3):261-5. PubMed ID: 22397496
[TBL] [Abstract][Full Text] [Related]
47. The apoptosis of non-small cell lung cancer induced by cisplatin through modulation of STIM1.
Li W; Zhang M; Xu L; Lin D; Cai S; Zou F
Exp Toxicol Pathol; 2013 Nov; 65(7-8):1073-81. PubMed ID: 23714431
[TBL] [Abstract][Full Text] [Related]
48. Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation.
Aung HH; Lame MW; Gohil K; An CI; Wilson DW; Rutledge JC
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2088-96. PubMed ID: 23868936
[TBL] [Abstract][Full Text] [Related]
49. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines.
Tanabe M; Izumi H; Ise T; Higuchi S; Yamori T; Yasumoto K; Kohno K
Cancer Res; 2003 Dec; 63(24):8592-5. PubMed ID: 14695168
[TBL] [Abstract][Full Text] [Related]
50. Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3.
Jan YH; Tsai HY; Yang CJ; Huang MS; Yang YF; Lai TC; Lee CH; Jeng YM; Huang CY; Su JL; Chuang YJ; Hsiao M
Cancer Res; 2012 Oct; 72(19):5119-29. PubMed ID: 23002211
[TBL] [Abstract][Full Text] [Related]
51. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells.
Ueda K; Kawashima H; Ohtani S; Deng WG; Ravoori M; Bankson J; Gao B; Girard L; Minna JD; Roth JA; Kundra V; Ji L
Cancer Res; 2006 Oct; 66(19):9682-90. PubMed ID: 17018626
[TBL] [Abstract][Full Text] [Related]
52. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Li J; Viallet J; Haura EB
Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
[TBL] [Abstract][Full Text] [Related]
53. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
54. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
[TBL] [Abstract][Full Text] [Related]
55. Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.
Eriksson M; Hååg P; Brzozowska B; Lipka M; Lisowska H; Lewensohn R; Wojcik A; Viktorsson K; Lundholm L
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):174-187. PubMed ID: 29107335
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
57. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
[TBL] [Abstract][Full Text] [Related]
58. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
[TBL] [Abstract][Full Text] [Related]
59. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
60. Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Hao ZF; Su YM; Wang CM; Yang RY
Tumour Biol; 2015 Mar; 36(3):1471-6. PubMed ID: 25371069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
